Incyte Ord Shs (INCY)

$96.93 0.32 (0.33%)

16:45 EDT INCY Stock Quote Delayed 30 Minutes

Volume:

Previous Close $96.93

Market Cap 20.55B

PE Ratio -127.54

EPS -0.76

Volume (Avg. Vol.) 760,500

Day's Range 95.93 - 98.35

52-Week Range 62.48 - 110.36

Dividend & Yield N/A (N/A)

INCY Stock Predictions, Articles, and Incyte Ord Shs News

From InvestorPlace
From the Web

5 Big Biotech Stocks To Buy In 2018

By Aaron Levitt, InvestorPlace Contributor Jan 17, 2018

Biotech stocks had a great run in 2017. The new year could have more big gains ahead. Here are 5 top biotech stocks to buy today.

5 Stocks the Top Fund Managers Love

By Harriet Lefton, Writer, TipRanks Nov 20, 2017

These top hedge fund stocks all have a 'very positive' confidence sentiment for the quarter and a 'Strong Buy' outlook from the Street.

Vapid Earnings Visibility Restrict Incyte (INCY) Rating

By Portfolio Grader Nov 6, 2017

Incyte Corp (NASDAQ:INCY) is a $22.2 billion in market value member of the Biotechnology GICS industry group where Portfolio Grader's current ranking for INCY puts it 171 among the 349 companies in this industry group, placing it in the top half. INCY is ranked in the third quartile of the sector with a ranking of 402 among the 785 companies in the sector and number 2,601 in the 5000 company Portfolio Grader company universe.

5 Toxic Stocks to Abandon or Sell Short for Gains

By Zacks Investment Research Oct 12, 2017

Toxic stocks are susceptible to external shocks and are loaded with high amounts of debts. Also, the price of toxic stocks is irrationally high.

5 Toxic Stocks to Discard or Sell Short for Profit

By Zacks Investment Research Sep 22, 2017

Toxic stocks are exposed to outside shocks and are burdened with high levels of debts. Also, the price of toxic stocks is artificially inflated.

5 of the Toughest Stocks to Withstand a Downturn

By Harriet Lefton, Writer, TipRanks Sep 18, 2017

These downturn-proof stocks to buy are much tougher than most on the market. Here's why each are among the toughest stocks to own.

Compare Brokers

5 Biotech Stocks That Are Breaking Higher

By Anthony Mirhaydari, InvestorPlace Market Strategist Aug 30, 2017

Biotech stocks are surging amid M&A speculation after Gilead agreed to buy Kite Pharma. And these biotechs are moving higher in response.

Incyte Corporation (INCY) Shares Drop on Q2 Loss

By Karl Utermohlen, InvestorPlace Writer Aug 1, 2017

Incyte Corporation (INCY) shares fell following the pharmaceutical company's fiscal second-quarter results, which saw earnings disappoint.

Why Herbalife Ltd. (HLF), Snap Inc (SNAP) and Incyte Corporation (INCY) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Jun 5, 2017

Incyte (INCY), Snap (SNAP) and Herbalife (HLF) shareholders should have made it a three-day weekend. Here's why.

Incyte Corporation (INCY) Stock Jumps on Promising Lung Cancer Drug

By William White, InvestorPlace Writer May 18, 2017

Incyte (INCY) stock was up on Thursday on promising results in Phase 1 and Phase 2 studies for one of its lung cancer drugs.

4 Biotech Stocks That Could Be Rocked and Rolled This Month

By James Brumley, InvestorPlace Feature Writer May 4, 2017

If you own any of these biotech stocks (or are thinking about it), mark these four dates on your calendar. Things are going to get real interesting, real fast.

Why Dish Network Corp (DISH), Snyder’s-Lance Inc (LNCE) and Incyte Corporation (INCY) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Apr 17, 2017

Incyte (INCY), Dish Network (DISH) and Snyder's-Lance (LNCE) shareholders ended up wishing this past weekend was a four-day trading break.

Compare Brokers

Eli Lilly and Co (LLY) Stock Holders Choke on FDA Letter for Barictinib

By Dana Blankenhorn, InvestorPlace Contributor Apr 17, 2017

Eli Lilly (LLY) took a hit Monday after an FDA letter on dosages and safety likely delayed Olumiant's U.S. market entry. But LLY stock still has its virtues.

The 10 Best Stocks of the S&P 500 in Q1

By Jeff Reeves Mar 31, 2017

While the markets have been performing well in general for the first quarter, some of the S&P 500's best stocks have really cut loose.

5 Top Stocks to Buy as Bull Market Turns Eight

By Zacks Investment Research Mar 9, 2017

We have selected 5 Buy-ranked stocks that have outperformed in the current bull market with room to run higher.

8 of the Most Overrated Stocks on Wall Street Right Now

By James Brumley, InvestorPlace Feature Writer Feb 27, 2017

Some stocks are graded fairly, but a handful of the most overrated stocks deserve to be called out -- and sold sooner than later.

5 Toxic Stocks to Dump or Play Short Now

By Zacks Investment Research Jan 26, 2017

Higher prices of toxic stocks can be attributed to irrational exuberance or serious fundamental lacuna. Here are 5 stocks to consider selling

37 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 26, 2016

This week, the overall grades of 37 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Compare Brokers